Search for: "Pfizer Inc. v. Government of India" Results 1 - 20 of 36
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Apr 2022, 7:48 am by Paul Stephan
Weltover, Inc., stated that because the government measure in question had satisfied due process, it had no need to decide whether the Constitution compelled this. [read post]
10 Jan 2022, 4:01 pm by INFORRM
The incident followed the publication of a peer-review article that questioned the integrity and regulatory oversight issues surrounding Pfizer’s phase III Covid-19 vaccine trial. [read post]
13 Jul 2021, 10:58 am by Simon Lester
In the United States (US), as for most developed countries,[6] trade policy and IP standards have consistently been linked, a pattern which can (at least partially) be traced back to extensive lobbying by senior management at US-based technology and pharmaceutical firms.[7] For example, since at least the 1980s, Pfizer Inc. has been involved in mobilizing other US firms and stakeholders to lobby US policymakers on the issue of international IP protection. [read post]
6 Nov 2020, 7:16 am by Dennis Crouch
  Mylan is set to merge with Pfizer later this calendar year. [read post]
17 Mar 2020, 1:32 pm by Noble McIntyre
Recalls are an important tool that the government uses to protect the public. [read post]
24 Feb 2010, 2:11 am
(IP Watch) Exploring a new angle in the TRIPS and drug patents debate (Spicy IP) EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas) EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas) India: Victory for access to medicines as Bayer loses lawsuit in… [read post]
24 Feb 2010, 2:11 am
(IP Watch) Exploring a new angle in the TRIPS and drug patents debate (Spicy IP) EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas) EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas) India: Victory for access to medicines as Bayer loses lawsuit in… [read post]
2 Dec 2009, 4:31 am
Because other countries just decide to pay less – Pfizer’s patent battle against UniLab (Patent Baristas) Moxifloxacin – Venezuela annuls two of Bayer’s patents relating to Moxifloxacin (IP tango) (IP tango) Plavix (Clopidogrel) – India: Indian company, Cadila, bears the brunt of section 3(d) (Spicy IP) Sanctura (Trospium) – US: Allergan files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs) Taxotere… [read post]
8 Jul 2009, 7:04 am
(Spicy IP) India: Novartis patent rejection by the IPAB: Accessing the decision (Spicy IP) (IAM) India: Likely corruption in the Indian health care sector – Public interest litigation over government shutdown of vaccine production plants to enter contracts with private sector (IP Osgoode) Kenya: Manufacturers, public heath interests clash over anti-counterfeit law; AIDS patients to bring Constitutional challenge (Intellectual Property Watch) (Afro-IP)… [read post]
5 Sep 2008, 11:01 pm
’s yodel first sound mark granted by India’s trade mark regis [read post]
29 Aug 2008, 1:25 pm
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: CAFC sets strict standards to establish inequitable conduct: Star Scientific v R J Reynolds Tobacco: (Hal Wegner), (Maryland Intellectual Property Law Blog), (Patent Prospector), (Patent Docs), (Patently-O), (more from Patently-O), (Philip Brooks), (Law360), (I/P Updates), Safe harbour ruling in Io v Veoh could help YouTube in Viacom… [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
18 Jul 2008, 8:34 am
: (GenericsWeb), Eularis analyses most effective generics defence strategies with new pharmaceutical industry report: (GenericsWeb), WIPO symposium to discuss life sciences multilateral environmental agreements: (Daily Dose of IP), Daiichi Sankyo and Ranbaxy confirm deal is binding and final, allay market rumour and speculation: (SmartBrief), Daiichi Ranbaxy takeover and the implications for the future of IP: (Spicy IP), Europe: Cancer Research Therapeutics’ RNAi patent revoked by EPO:… [read post]
11 Jul 2008, 4:30 am
: (IAM), (Patent Circle), India takes open source approach to drug discovery: (Patent Lens), India: Indian Bayh Dole Bill: (Spicy IP), (Spicy IP), (Does India need Bayh-Dole? [read post]
27 Jun 2008, 10:04 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Court reconsidering baseless ‘making available’ theory in file-sharing case Capitol Records v Jammie Thomas; amicus briefs from, MPAA, PFF: (Electronic Frontier Foundation), (Electronic Fontier Foundation), (Techdirt), (Ars Technica), (Patry Copyright Blog), (Patry Copyright Blog) ICANN approves rules allowing brands to be… [read post]
20 Jun 2008, 8:07 am
– Comments on IPEG post on Zyprexa patent case: (BLOG@IP::JUR) India takes open source approach to drug discovery: (Patent Lens), India: Is the Indian Drug Controller participating in the ACTA negotiations? [read post]
30 May 2008, 9:09 am
: (Spicy IP), India: DCGI preparing document to implement patent-registration linkage: (Spicy IP), New Zealand: Generic pharmaceutical companies taking advantage of NZ IP laws and medicines regulations: (International Law Office), Uganda: Cipla licenses ARV technology into Uganda: (Afro-IP), US: Money saved through generic prescriptions: (GenericsWeb), US: Government plans to keep close tab on drug patent settlements: (GenericsWeb), US: FTC reports 14 deals to delay generics in… [read post]